Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non–small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials
The optimal first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for EGFR-mutant advanced non–small cell lung cancer (NSCLC) remains uncertain due to the availability of multiple generations of TKIs and limited head-to-head comparisons. A systematic review and network meta-analysis (NMA) o...